Material transfer agreements look small. A few pages, a vial of cell line or a plasmid, a signature from a university tech transfer office. Research contracts managers at biotech companies often handle dozens of them in a quarter, inbound and outbound, and most get signed, filed and forgotten. That is where the risk starts.
An MTA is a live set of obligations that runs as long as the material sits in a freezer or a derivative sits in a notebook. It limits what scientists can do, sets publication review windows, controls who owns inventions, and requires return or destruction at the end. When nobody tracks those terms after signature, the company can drift into breach without anyone noticing, and the first sign is often a dispute over a patent filing or a paper.
This guide is for alliance and research contracts managers who want material transfer agreement management to work like any other obligation program: every agreement captured, every term extracted, every deadline owned by a named person, and every material accounted for at close.
What an MTA actually governs
Most MTAs share the same core structure whether they come from an academic lab, a commercial partner or your own outbound template. The details change, but the obligation categories repeat. A useful extraction model covers at least these areas.
- Materials and permitted use, the specific material, quantity, and the research purpose it may be used for, usually tied to a described project or protocol.
- Use restrictions, typically no use in humans, no clinical use, no commercial use, and no transfer to third parties without written consent from the provider.
- Derivatives and modifications, how the agreement treats progeny, unmodified derivatives and modified material, and which of those remain the provider's property.
- Publication and confidentiality, review windows before submission, the right to request removal of confidential information, and delay periods to allow patent filings.
- IP, term and end of use, invention reporting duties, any license option, the agreement term, and the requirement to return or destroy remaining material at expiry or termination.
Many academic institutions use the Uniform Biological Material Transfer Agreement, or UBMTA, a standard master agreement that participating institutions accept so that individual transfers can be documented with a short implementing letter. It defines terms such as original material, progeny, unmodified derivatives and modifications, and it restricts use to teaching and academic research. Teams should still read the implementing letter carefully, because it carries the specifics of each transfer, and commercial recipients may be asked to sign a different agreement altogether.
The signed PDF is evidence. The obligations inside it, use limits, review windows, destruction dates and invention reports, are the things that need owners, reminders and proof of completion.
Where MTA programs usually break
Failures in MTA programs rarely come from bad drafting. They come from the gap between the contracts team, which negotiates the terms, and the lab, which lives with them. Research contracts managers commonly report the same handful of patterns.
- Use drifts beyond scope. A material received for one assay ends up in a second project, a collaboration with another partner, or an animal study the agreement never contemplated, and nobody checks the permitted use.
- Publication review windows are missed. A scientist submits an abstract or manuscript without sending it to the provider first, and the review period in the MTA is breached before anyone in legal hears about the paper.
- Materials are never returned or destroyed. Agreements expire while tubes remain in storage, and there is no certificate of destruction or return record to show the provider or an acquirer in diligence.
- Derivatives go untracked. Modified constructs and progeny are logged in lab systems without any link back to the source MTA, which makes ownership and reporting duties hard to reconstruct later.
- Invention reporting is late. A discovery that used provider material is disclosed internally but never reported to the provider under the agreement, creating friction when the company files a patent.
A five step roadmap for MTA management
Step 1, Build a single inventory of every MTA
Start by collecting inbound and outbound agreements from shared drives, inboxes, tech transfer portals and lab notebooks into one repository. Tag each record with direction, counterparty, principal investigator, material description, execution date and status. Include UBMTA implementing letters as their own records linked to the master agreement. Expect to find agreements nobody knew existed.
Step 2, Extract obligations into structured fields
Once the documents are in one place, pull the obligations out of the text. Use AI-assisted extraction to capture permitted use, use restrictions, publication review period, confidentiality term, invention reporting duty, derivative treatment, agreement term and end-of-term disposition. Have a contracts manager confirm each extracted field against the source clause. Structured fields are what make reporting possible, since you cannot query a PDF for every agreement with a 60-day review window.
Step 3, Assign owners on both sides of the bench
Every obligation needs a named owner. Legal or alliance management owns the contract, but the principal investigator owns day-to-day compliance with use restrictions and publication review. Record both. Connect the MTA record to the lab's project or protocol identifier so that a new study using the same material triggers a scope check. This is the same pattern teams use for investigator obligations in clinical trial agreement automation, and the two programs benefit from sharing an owner model.
Step 4, Automate reminders and review workflows
Set reminders for the dates that matter: publication submissions, invention reporting windows, agreement expiry and the deadline for return or destruction. Route publication drafts through a simple intake workflow so that scientists can flag an upcoming paper and the contracts team can check which MTAs cover the materials used. Escalate overdue items to the investigator's manager, not only to legal. The goal is a prompt that reaches the person who can act before the deadline passes.
Step 5, Close out with evidence
At expiry or termination, confirm the disposition of remaining material and collect evidence: a signed certificate of destruction, a return shipment record or a written consent to retain. Attach it to the MTA record and mark the obligation complete. Log any derivatives that survive under the agreement's terms. Closed records with evidence are what you hand to a provider, auditor or acquirer's diligence team.
See MTA obligations tracked end to end
Aavenir extracts MTA terms, assigns owners and tracks publication reviews and destruction deadlines in one place.
How MTA tracking fits your broader obligation program
MTAs sit next to clinical trial agreements, research collaborations, sponsored research agreements and licenses in most biotech contract portfolios. They share obligation types: confidentiality, publication control, IP reporting and record retention. Running them in separate spreadsheets means duplicated owner lists, inconsistent reminders and no single view of what the company owes each university. A shared obligation model shows every commitment to a given institution at once. The life sciences obligation management datasheet shows how these obligation types map to one structure.
What to track for every MTA
The table below is a practical starting field map. Adjust it to your own templates, but keep each obligation tied to an owner and a piece of evidence.
| Obligation | What to capture | Evidence of compliance |
|---|---|---|
| Permitted use | Research purpose, project or protocol, excluded uses such as human or clinical use | Scope check logged when material is assigned to a new study |
| Publication review | Review window, delay period for patent filing, provider contact | Date draft sent to provider and response received |
| Derivatives and modifications | Definitions, ownership, whether transfer of derivatives is allowed | Lab records linking derivatives to the source MTA |
| Invention reporting | Reporting trigger, timing, any license option or negotiation right | Written notice to provider with date and summary |
| Return or destruction | Term, expiry date, disposition required at end of term | Certificate of destruction or return shipment record |
Good material transfer agreement management is not about more paperwork. It is about knowing, for every agreement, what the lab may do, what it must tell the provider and when, and what happens to the material at the end. Capture the terms once, assign owners across legal and the lab, automate the reminders and close each agreement with evidence. The result is a program that holds up when a provider asks a hard question.
For related guidance, see Seismic data license agreement tracking for E&P teams, Investigator initiated study agreements, a practical guide and Price adjustment clauses in direct material contracts.
